Cinqair (reslizumab) / Merck (MSD), UCB, Teva - LARVOL DELTA

Biologics in Severe Asthma: From Precision Phenotyping to Clinical Remission. (PubMed, J Asthma) - "We included pivotal randomized controlled trials, real-world evidence studies, systematic reviews, and meta-analyses focusing on approved biologics (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab) and emerging agents for severe asthma. Biologics have made clinical remission an attainable goal for many patients. Future research must focus on therapies for non-type 2 asthma, refining dynamic biomarkers, and establishing long-term disease-modifying effects."

Journal • Review • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

The Impact of BMI on the Effect of Biologic Agents for Severe Asthma. (PubMed, Pulm Ther) - "Biologic agents are effective treatments for severe asthma, although mepolizumab, benralizumab, and reslizumab appear to have better results in patients with lower BMI. Dupilumab appears to be equally effective across all BMI categories, while no data are available for tezepelumab. More studies in patient populations with severe asthma and comorbid obesity are needed to evaluate the effectiveness of biologic therapies in this specific category of patients."

Journal • Review • Asthma • Genetic Disorders • Immunology • Obesity • Pulmonary Disease • Respiratory Diseases

COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR SEVERE ASTHMA: A SYSTEMATIC LITERATURE REVIEW (ISPOR 2026) - "The biologic therapies assessed in the included studies comprised omalizumab, mepolizumab, benralizumab, reslizumab, tezepelumab, and dupilumab. Benralizumab showed the most consistent cost-effectiveness across the included evidence. Dupilumab and tezepelumab appeared favorable but were supported by limited studies; findings for mepolizumab were mixed. As clinical evidence for recently introduced biologics in asthma continues to grow, synthesizing cost-effectiveness evidence for these treatments can inform future clinical and economic research and support more equitable allocation of scarce healthcare resources."

Cost effectiveness • HEOR • Review • Asthma • Immunology • Respiratory Diseases

Depemokimab (Exdensur) for severe eosinophilic asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Biologic Adherence and Exacerbation Risk Among Patients With Severe Asthma in the CHRONICLE Study (AAAAI 2026) - P | "This analysis included data from participants enrolled between February 2018 and February 2024 who initiated a biologic (benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, or tezepelumab) and remained on treatment for ≥52 weeks. Among patients with ≥2 exacerbations in the prior year, higher biologic adherence was associated with higher biologic effectiveness. Conclusions Among US adults with uncontrolled SA, lower biologic adherence was associated with reduced real-world treatment effectiveness in terms of reducing exacerbations."

Adherence • Clinical • Asthma • Immunology • Respiratory Diseases

Type 2 Biomarkers as Mediators of Clinical Remission with Biologics in Severe Asthma (AAAAI 2026) - "Methods A total of 342 patients with SA were followed for ≥12 months: 51 received conventional therapy (Con-Tx), 123 received anti-IL5/IL5R therapy (benralizumab n=47, mepolizumab n=48, reslizumab n=28), and 168 received anti-IL4R therapy (dupilumab). MA confirmed statistically significant mediation by FeNO (p=0.045) and Sp-EOS (p=0.002). Conclusions Anti-IL5/IL5R therapy promotes CR via reductions in BEC and Sp-EOS, whereas anti-IL4R therapy achieves CR primarily through reductions in Sp-EOS and FeNO."

Biomarker • Clinical • Asthma • Immunology • Respiratory Diseases • IL5

Biologic therapies for severe pediatric asthma: efficacy, safety, and biomarker-guided selection. (PubMed, Front Allergy) - "Targeted biologics, anti-IgE (omalizumab), anti-IL-5/IL-5Rα (mepolizumab, benralizumab; pediatric data for reslizumab remain limited), anti-IL-4Rα (dupilumab), and anti-TSLP (tezepelumab) improve disease control, reduce severe exacerbations, and enable steroid-sparing in appropriately selected children. Biologic therapies have reshaped the care of severe pediatric asthma, operationalizing precision medicine through immunologic endotyping and biomarker-guided selection. Priorities now include standardized definitions of response and remission, robust long-term safety data, and strategies to ensure equitable access across diverse pediatric populations."

Biomarker • Journal • Review • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases • IL13 • IL4 • IL5

Effectiveness of biologics for reducing occlusive mucus plugs in patients with severe asthma: a systematic review. (PubMed, Respir Res) - "Three placebo-controlled randomized controlled trials (RCTs) were identified; one RCT of tezepelumab in patients across baseline blood eosinophil counts (BECs) and fractional exhaled nitric oxide (FeNO) levels and two RCTs of dupilumab in those with elevated BECs or sputum eosinophils and/or elevated FeNO levels...Other biologics (benralizumab, mepolizumab, omalizumab and reslizumab) were evaluated in observational studies without a placebo control, demonstrating reductions in mucus plug scores after treatment...All studies showed residual plugs after biologic intervention, demonstrating a need for further understanding of how best to quantify and characterize mucus plugs to predict their response to treatment and develop optimal, individualised treatment strategies. This review highlights the relevance of assessing and targeting mucus plugs in clinical practice to help optimise patient outcomes."

Journal • Review • Asthma • Eosinophilia • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Using biomarkers and independent predictors of therapy response to optimize treatment of uncontrolled severe asthma in the biologic era. (PubMed, Front Allergy) - "An improved mechanistic understanding of asthma has revealed that many cases are driven by type 2 inflammation, which can be targeted with biologic agents including omalizumab (anti-IgE), mepolizumab and reslizumab (anti-IL-5), benralizumab (anti-IL-5Rα), dupilumab (anti-IL-4Rα), and tezepelumab (anti-thymic stromal lymphopoietin). In this review, I briefly examine the current state of biologics and biomarkers in the treatment of uncontrolled severe asthma, and draw on my clinical experience to highlight limitations to optimal management, including persistent treatment heterogeneity. After discussing emerging biomarkers and predictors of disease status and treatment response, I provide my perspective on future approaches and research directions that may enhance clinical treatment and improve patient outcomes."

Biomarker • Journal • Review • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL5 • TSLP

A Case of an 80-Year-Old Woman With Chronic Eosinophilic Pneumonia and Clinically Significant Giant Hepatic Hemangioma. (PubMed, Cureus) - "The patient's CEP was well controlled after desensitization to reslizumab, which initially induced urticaria...While larger hemangiomas have been reported, this case demonstrates that even in the elderly, with multiple co-morbidities, one may tolerate a growing mega hepatic hemangioma. Age and comorbidity may preclude operative therapy."

Journal • Allergy • Dermatology • Hepatology • Immunology • Infectious Disease • Liver Cancer • Mood Disorders • Musculoskeletal Pain • Oncology • Osteoporosis • Pneumonia • Psychiatry • Pulmonary Disease • Respiratory Diseases • Rheumatology • Urticaria

Comparative analysis of the manufacturing carbon footprint of biologics for severe asthma. (PubMed, BMJ Open) - "The carbon footprints of biologic treatments for severe asthma vary widely, driven primarily by differences in dose and manufacturer electricity sources. Our analyses highlight near-term opportunities to reduce emissions, including replacing fossil fuel electricity with renewable or nuclear sources (NFFE) and optimising dosing practices. The approach can be applied across other therapeutic areas to support carbon-informed prescribing and healthcare decarbonisation."

Clinical • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Global prevalence of eligibility for biologic therapy in ATS/ERS-defined severe asthma: A systematic review. (PubMed, World Allergy Organ J) - "Following PRISMA guidelines (PROSPERO CRD42023393897), we searched MEDLINE, EMBASE, Web of Science, and ClinicalTrials.gov for studies published between 2000 and 2025 that reported the proportion of biologic-naïve, severe asthma patients eligible for omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, or tezepelumab. Globally, approximately 51% of adults with severe asthma are eligible for biologic therapy, excluding tezepelumab. Among available biologics, eligibility is generally higher for anti-IL5/IL5Rα therapies than for anti-IgE, and appears highest for anti-IL4Rα, although data for the latter remain limited."

Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL5

Real-world outcomes after anti-IL-5/anti-IL-5Rα treatment for hypereosinophilic syndrome: Systematic literature review. (PubMed, J Allergy Clin Immunol Glob) - "This systematic literature review searched English-language articles (November 4, 2015, to October 31, 2023) and conference abstracts (January 1, 2021, to October 31, 2023) from MEDLINE/Embase and select conferences for publications containing outcomes for patients with HES receiving anti-IL-5 (mepolizumab [approved], reslizumab) or anti-IL-5Rα (benralizumab) treatment in the real world. Of those receiving benralizumab or mepolizumab, OCS dose was reduced in 49.0% to 100% of patients from cohort studies, and by ≥50% in 29 of 70 patients from case reports. Real-world anti-IL-5/anti-IL-5Rα therapy in HES is associated with fewer flares as well as reductions in bEOS counts and OCS dose, although confirmatory studies in larger populations are needed."

Journal • Real-world evidence • Eosinophilia • Hypereosinophilic Syndrome • Immunology • IL5

Overview of Biologics Targeting Type 2 Inflammation in Respiratory Disease. (PubMed, J Allergy Clin Immunol Pract) - "Developed to treat more severe forms of asthma, the available biologics- benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, and tezepelumab- have been successfully applied to treat other diseases of the upper and lower airways. Selecting the right treatment- that which is most effective- can be a challenge. In this review, we provide practical and evidence-based recommendations about selecting a type 2 biologic across the spectrum of respiratory diseases."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Chronic Rhinosinusitis With Nasal Polyps • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Inflammation • Langerhans Cell Histiocytosis • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Sinusitis • Vasculitis

A review of the safety of antibody therapy in severe eosinophilic asthma. (PubMed, Expert Rev Respir Med) - "This review evaluates the safety profiles of currently approved biologics for SEA, including mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab. Current evidence indicates that biologic therapies for SEA are safe and well tolerated, with serious adverse events being rare. Nevertheless, long-term and comparative safety data remain limited, and ongoing pharmacovigilance and post-marketing surveillance are essential to fully define risk profiles."

Journal • Review • Asthma • Conjunctivitis • Eosinophilia • Immunology • Infectious Disease • Inflammation • Musculoskeletal Pain • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain • Pulmonary Disease • Respiratory Diseases • IL5

Rapid Desensitization to Reslizumab in an 80-Year-Old Woman With Chronic Eosinophilic Pneumonia, Severe Persistent Asthma, and Chronic Urticaria. (PubMed, Cureus) - "In treating her CEP and severe asthma, she trialed monoclonal antibody therapy with mepolizumab, benralizumab, dupilumab, and omalizumab, which were each begun and then discontinued successively due to severe side effects or allergic reaction. Our patient reported notable relief of dyspnea and fatigue at two weeks and four weeks post-procedure. As opposed to a decrease in dose or discontinuation of treatment, patients may undergo rapid desensitization through a stepwise, slowed infusion rate to better tolerate a previously allergenic medication."

Journal • Allergy • Asthma • Cardiovascular • Dermatology • Fatigue • Immunology • Infectious Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • Urticaria

Siglec-8 as a Biomarker for Predicting Anti-IL-5 Response in Severe Asthma. (PubMed, Allergy Asthma Immunol Res) - P | "Baseline serum Siglec-8 levels showed a trend toward better predictive performance than other parameters for predicting 6- and 12-month responses to anti-IL-5 therapies in patients with SA. These findings suggest that Siglec-8 may have the potential as a biomarker for guiding treatment decisions, although further validation in larger, prospective studies is warranted."

Biomarker • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL5 • SIGLEC8

Proteomic Identification of Plasma Biomarkers of Response to IL-5 Inhibitor Biologics in Healthy Subjects. (PubMed, Clin Transl Sci) - "In this study, we profiled over 7000 plasma proteins to identify potential PD biomarkers for the interleukin-5 (IL-5) inhibitors mepolizumab and reslizumab, which are approved for treating eosinophilic asthma. Both biomarkers showed dose-response trends and comparable variability to placebo. Our study identified EMBP and PRG3 as promising plasma PD biomarkers for IL-5 inhibitors, warranting further validation for early phase trials and biosimilar development programs."

Biomarker • Clinical • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • AIFM2 • IL5

Impact of SARS-CoV-2 on Severe Asthma Patients Undergoing Biological Therapy: A Multicenter Study. (PubMed, J Clin Med) - "Participants received omalizumab, mepolizumab, benralizumab, or reslizumab. Patients receiving biologics did not experience worse outcomes than the general population, and no biologic was linked to poorer COVID-19 prognosis. Vaccination further contributed to protection against severe disease."

Clinical • Journal • Asthma • Immunology • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Glucocorticoid Treatment in Severe Asthma. (PubMed, Semin Respir Crit Care Med) - "Biologic therapies targeting IgE (omalizumab), IL-5 (mepolizumab, reslizumab), IL-5Rα (benralizumab), IL-4Rα (dupilumab), and TSLP (tezepelumab) have shown substantial OCS-sparing effects in clinical trials, enabling dose reduction or discontinuation in many patients with steroid-dependent asthma. In conclusion, while glucocorticoids remain essential for acute exacerbations and as bridging therapy, their chronic use should be minimized. Biologic therapies offer a transformative opportunity to reduce glucocorticoid burden, improving long-term outcomes and quality of life in patients with severe asthma."

Journal • Asthma • Diabetes • Eosinophilia • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Obesity • Osteoporosis • Psychiatry • Pulmonary Disease • Respiratory Diseases • Rheumatology • HDAC2 • IL13 • IL4 • IL5 • TSLP

Comparative Analysis of Patient-Reported Outcomes (PROs) in Asthma Biologic Late-Phase Studies and Approved Labels: Implications for Entry and Product Differentiation (ISPOR-EU 2025) - "This analysis aims to inform endpoint selection for future clinical development and labelling. A review of FDA and EMA labels, regulatory feedback, health authority reviews, and pivotal trial designs was conducted for approved asthma biologics (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab) and trial designs for late phase studies (depemokimab, dexpremispexole) in May 2025. ACQ-5 and AQLQ responder and change from baseline endpoints are established entry criteria for asthma biologics, with regulatory precedent supporting their inclusion. Symptom diary endpoints and other novel endpoints addressing patient-prioritized outcomes offer opportunities for differentiation. This review provided cross-asset competitive and regulatory intelligence supporting strategic clinical design for best-in-class labelling."

Clinical • Patient reported outcomes • Asthma • Immunology • Respiratory Diseases

Dual Biologic Therapy in Refractory Eosinophilic Esophagitis with Systemic Hypereosinophilia: A Case Report (ACAAI 2025) - "Despite trials of anti-IL-5 therapies (reslizumab and benralizumab) for eosinophilic asthma, his EoE symptoms persisted. Combination biologic therapy with dupilumab and benralizumab was pursued to target systemic eosinophilia. This case underscores the need for personalized treatment strategies in refractory eosinophilic disorders and supports the role of dual biologic therapy in selected cases."

Case report • Clinical • Allergic Rhinitis • Asthma • Eosinophilia • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • Inflammation • Respiratory Diseases • IL5

Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study (ACR Convergence 2025) - "Previous immunosuppressive therapies included azathioprine (22%), methotrexate (13.6%), mycophenolate mofetil (9%), and cyclophosphamide (9%)...Most commonly were Mepolizumab (50%), Omalizumab (40%), and Reslizumab (10%).Benralizumab was initiated a mean of 4.6±4 years post-EGPA diagnosis (30 mg subcutaneously every 4 weeks). Showed a rapid and sustained improvements over 60 months: a) FEV₁ increased from median 1935 [1545-2680] to 2270 [2192.5-2460] mL (p=0.0312), b) eosinophil counts dropped from 850 [740-1100]/mm³ to 0 [0-0] (p< 0.0001), c) serum IgE levels decreased from 225 [57-360] (IU/mL) to 158.5 [115-217] IU/mL; (p=0.125) and, d) prednisone dose from 5 mg/day [2.5-10] to 0 [0-0]; (p=< 0.0001)After a mean follow-up of 42.4±20.7 months 78.2% of patients remained in remission. Benralizumab demonstrated rapid and sustained effectiveness, even in patients with severe and refractory EGPA, consistent with findings from clinical trials. These..."

Clinical • Real-world • Real-world evidence • Asthma • Eosinophilia • Eosinophilic Granulomatosis With Polyangiitis • Immunology • Langerhans Cell Histiocytosis • Rare Diseases • Respiratory Diseases • Vasculitis

COMPARATIVE OUTCOMES OF BIOLOGICS IN ASTHMA-COPD OVERLAP VS ASTHMA: A REAL-WORLD ANALYSIS (CHEST 2025) - "We identified patients with either asthma-COPD overlap or bronchial asthma receiving omalizumab, dupilumab, reslizumab, mepolizumab, tezepelumab, or benralizumab for at least six months. Despite biologic therapy, those with asthma-COPD overlap had worse outcomes than purely asthmatic patients, indicating a more severe disease phenotype. Higher rates of respiratory failure, exacerbations, and healthcare utilization underscore an unmet need for integrated care pathways addressing the combined features of asthma and COPD. Although biologics target key inflammatory pathways, concurrent COPD-related pathophysiology may limit their efficacy."

Clinical • Real-world • Real-world evidence • Asthma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diabetes • Genetic Disorders • Hypertension • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder • Tobacco Cessation

IMPACT OF PSYCHOLOGICAL STRESS ON DISEASE CONTROL AMONG SUBJECTS TREATED BY BIOLOGICAL THERAPIES FOR SEVERE ASTHMA (CHEST 2025) - "Biological therapies were benralizumab 13/44 (29.5%), dupilumab 11/44 (25%), mepolizumab 10/44 (22.7%), tezepelumab 5/44 (11.4%), omalizumab 4/44 (9.1%), and reslizumab in 1 patient (2.3%). Worsening of asthma occurred in the majority of patients receiving biological therapies for severe asthma following the October 7 th events, including individuals on remission. CLINICAL IMPLICATIONS: Biological therapy does not protect from the deleterious effects of emotional stress on asthma. The mechanisms of asthma worsening following emotional stress does not seem to include eosinophilic inflammation."

Clinical • Asthma • Immunology • Inflammation • Mood Disorders • Psychiatry • Respiratory Diseases